Joseph E Rower1,2, Amber D King1,2, Diana Wilkins2,3, Jacob Wilkes4, Venkata Yellepeddi5, Luke Maese6, Richard S Lemons6, Jonathan E Constance5. 1. Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA. 2. Center for Human Toxicology, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA. 3. Department of Pathology, University of Utah, Salt Lake City, Utah, USA. 4. Pediatric Analytics, Intermountain Healthcare, Salt Lake City, Utah, USA. 5. Division of Clinical Pharmacology, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, Utah, USA. 6. Division of Hematology and Oncology, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Abstract
Purpose: The therapeutic utility of Cannabis in cancer is a topic of intense interest. Dronabinol is synthetic Δ9-tetrahydrocannabinol (THC), the primary psychoactive component of Cannabis sativa, and is approved for treating refractory chemotherapy-induced nausea and vomiting. Little is known about dronabinol prescribing in children and young adults, and no published concentration data are available. This study evaluated national level dronabinol use and assessed concentrations of THC and its primary metabolites in patients with cancer <27 years of age prescribed dronabinol. Methods: Observational review of records from the Pediatric Health Information System (PHIS) and a regional network of hospitals in the Intermountain West, including a tertiary care children's hospital, Primary Children's Hospital (PCH), for inpatients <27 years of age prescribed dronabinol. Prospective blood samples were collected from children with cancer at PCH. Results: Across PHIS institutions, overall dronabinol prescribing aligned with the pharmacy records for those with cancer (p < 0.0001), and of these, 10.4% received dronabinol as inpatients. Blood collected within 72 hours of dronabinol administration was available from 10 children with a median age of 12.5 (range 6-17) years. Quantifiable concentrations were found in 4 (13%), 6 (20%), and 1 (3%) samples assayed for THC, 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (COOH-THC), and 11-hydroxy-Δ9-tetrahydrocannabinol (OH-THC), respectively. THC concentrations ranged between 0.100 and 0.128 ng/mL and were not associated with dose. Conclusion: Dronabinol prescribing appears exclusive to patients diagnosed with cancer, and its use has increased steadily in the past decade. In a small sample of children administered dronabinol, THC and metabolite concentrations were consistently low or undetectable.
Purpose: The therapeutic utility of Cannabis in cancer is a topic of intense interest. Dronabinol is synthetic Δ9-tetrahydrocannabinol (THC), the primary psychoactive component of Cannabis sativa, and is approved for treating refractory chemotherapy-induced nausea and vomiting. Little is known about dronabinol prescribing in children and young adults, and no published concentration data are available. This study evaluated national level dronabinol use and assessed concentrations of THC and its primary metabolites in patients with cancer <27 years of age prescribed dronabinol. Methods: Observational review of records from the Pediatric Health Information System (PHIS) and a regional network of hospitals in the Intermountain West, including a tertiary care children's hospital, Primary Children's Hospital (PCH), for inpatients <27 years of age prescribed dronabinol. Prospective blood samples were collected from children with cancer at PCH. Results: Across PHIS institutions, overall dronabinol prescribing aligned with the pharmacy records for those with cancer (p < 0.0001), and of these, 10.4% received dronabinol as inpatients. Blood collected within 72 hours of dronabinol administration was available from 10 children with a median age of 12.5 (range 6-17) years. Quantifiable concentrations were found in 4 (13%), 6 (20%), and 1 (3%) samples assayed for THC, 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (COOH-THC), and 11-hydroxy-Δ9-tetrahydrocannabinol (OH-THC), respectively. THC concentrations ranged between 0.100 and 0.128 ng/mL and were not associated with dose. Conclusion: Dronabinol prescribing appears exclusive to patients diagnosed with cancer, and its use has increased steadily in the past decade. In a small sample of children administered dronabinol, THC and metabolite concentrations were consistently low or undetectable.
Entities:
Keywords:
chemotherapy-induced nausea and vomiting (CINV); dronabinol; orexigenic; tetrahydrocannabinol
Authors: Aminah Jatoi; Harold E Windschitl; Charles L Loprinzi; Jeff A Sloan; Shaker R Dakhil; James A Mailliard; Sarode Pundaleeka; Carl G Kardinal; Tom R Fitch; James E Krook; Paul J Novotny; Brad Christensen Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Garry Milman; Mateus M Bergamaschi; Dayong Lee; Damodara R Mendu; Allan J Barnes; Ryan Vandrey; Marilyn A Huestis Journal: Ther Drug Monit Date: 2014-04 Impact factor: 3.681
Authors: Yolanda Escobar; Gerardo Cajaraville; Juan Antonio Virizuela; Rosa Álvarez; Andrés Muñoz; Olatz Olariaga; María José Tamés; Begoña Muros; María Jose Lecumberri; Jaime Feliu; Purificación Martínez; Juan Carlos Adansa; María José Martínez; Rafael López; Ana Blasco; Pere Gascón; Virginia Calvo; Pablo Luna; Joaquín Montalar; Patricia Del Barrio; María Victoria Tornamira Journal: Support Care Cancer Date: 2015-06-17 Impact factor: 3.603
Authors: Babak Baban; Hesam Khodadadi; Évila Lopes Salles; Vincenzo Costigliola; John C Morgan; David C Hess; Kumar Vaibhav; Krishnan M Dhandapani; Jack C Yu Journal: Ageing Res Rev Date: 2021-10-15 Impact factor: 10.895